BioGraph 55
$11.8M
Funding date
Valuation / Funding
No funding history available
Funding data has not been imported for this company yet
Current Valuation Metrics
BioGraph 55 is currently valued at $25.0M as of June 1, 2024. The company has raised a total of $20.1M in funding.
Capital Efficiency
With a capital efficiency ratio of 1.24x, BioGraph 55 has achieved a valuation that is 1.24 times the total capital raised. This metric indicates room for improvement in capital deployment.
Investment Perspective
BioGraph 55's valuation reflects investor confidence in the company's market position, growth potential, and ability to execute on its business model. Private market valuations are determined by primary funding rounds and secondary market transactions, which take into account financial performance, market conditions, and growth prospects.
What is BioGraph 55 Worth in 2025?
As of 2025, BioGraph 55 is valued at $25.0M, based on the company's Later Stage VC funding round in June 1, 2024. This valuation positions BioGraph 55 as one of the leading private companies in the sector.
BioGraph 55 Valuation History
BioGraph 55's funding history demonstrates steady growth and investor confidence.
How BioGraph 55 Valuation is Determined
Private company valuations like BioGraph 55's are determined through primary funding rounds led by venture capital firms, private equity investors, and strategic partners. The valuation reflects factors including:
- Revenue growth and financial performance
- Market opportunity and total addressable market (TAM)
- Competitive positioning and market share
- Management team strength and execution capability
- Technology and intellectual property
- Industry trends and investor sentiment
BioGraph 55 Valuation FAQs
Is BioGraph 55 profitable?
BioGraph 55 has not publicly disclosed its profitability status. Many high-growth private companies prioritize market expansion and user growth over profitability in their early stages.
How does BioGraph 55's valuation compare to competitors?
BioGraph 55 is valued at $25.0M, positioning it as a major player in the space. Secondary market pricing and private market transactions provide ongoing validation of this valuation.
When will BioGraph 55 IPO?
BioGraph 55 has not announced plans for an initial public offering. Until an IPO, investors can access BioGraph 55 shares through secondary market platforms.